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ABSTRACT 
Glioblastoma multiforme is a common form of brain tumor that leads to debilitating effects 
despite the current regiment of treatment, which includes surgery, chemotherapy and 
radiotherapy. With the discovery of glioma-initiating cells (GICs) that exists within the bulk 
tumor, some light has been shed on this disease. GICs have been shown to be resistant to 
chemotherapy and radiotherapy, therefore providing a plausible explanation for the high 
propensity for recurrence in patients. However, effective treatments are still unavailable, and 
there is an urgency to discover drugs that can eradicate this group of cells. The overall aim of 
this thesis is to identify drugs from small molecule screens that can kill GICs, as well as to 
understand the possible causes and mechanisms for drug sensitivity.  
In Paper I, we have identified a new small molecule, Vacquinol-1, that reduced the viability 
and growth of GICs, both in vitro and in vivo, and had little effects on normal cells such as 
fibroblasts and embryonic stem cells. Cell death was caused by an unconventional non-
apoptotic manner, where the cells showed massive accumulation of vacuoles that formed 
through macropinocytosis. This led to the impairment of cell function followed by cell death. 
Furthermore, treatment with Vacquinol-1 also exhibited excellent improvement in survival of 
glioma xenografted mice. Using an shRNA screen, mitogen-activated protein kinase kinase 4 
(MKK4), which is involved in stress response, was determined to play a role in the unique 
type of cell death.  
In Paper II, we have identified that GICs are particularly sensitive to perturbations in calcium 
(Ca2+) homeostasis, with the relative degree of sensitivity being linked to their degree of 
stemness. The two compounds employed in this study, Ca2+ ionophore A23187 and the 
sarco/endoplasmic reticulum Ca2+-ATPase (SERCA) pump inhibitor Thapsigargin, are well-
known compounds that elicit cell death. However, the compounds affected viability to a 
different degree in the various GIC lines, with the line that is more similar to neural stem cells 
being more sensitive to perturbations in Ca2+ homeostasis. This sensitivity was correlated to 
expression levels of different Ca2+ related proteins such as GRIA1 and S100A6, as well as to 
Nestin (NES). 
In Paper III, we have repositioned Niguldipine, an old anti-hypertensive drug, as a potential 
compound for targeting GICs. Through an ion channel drug screen, we have also observed 
that GICs exhibit sensitivity to Ca2+ modulators, suggesting once again that Ca2+ homeostasis 
is critical to cell viability in GICs. Niguldipine, which is also a Ca2+ channel inhibitor, also 
showed a selection for GICs as compared to normal cells such as fibroblasts and neural stem 
cells. At the effective dose, the compound showed no effects on cardiac rhythmicity, and 
administration of the drug resulted in a significant improvement in the survival of glioma 
xenografted mice. 
In conclusion, we have identified a few small molecules, both old and new, that can reduce 
the proliferation and viability of GICs without affecting that of normal cells. One of the 
mechanisms underlying selectivity is that GICs show a greater degree of sensitivity to 
disturbances in Ca2+ homeostasis, therefore suggesting that Ca2+ modulators should be 
screened for their potential in cancer therapy. 
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1 INTRODUCTION 
1.1 CANCER STEM CELLS 
It has long been established that cancer is driven by the acquisition of various types of genetic 
alterations such as activation of oncogenes, gene amplification and the repression of tumor 
suppressors in normal differentiated cells. For many decades, cancer studies have been based 
on a stochastic model of oncogenesis where all cells have the same probability of becoming a 
cancer cell via the accumulation of sufficient mutations [1,2]. However, it was always an 
enigma how terminally differentiated, non-dividing cells are able to accumulate enough 
mutations to enable continuous replication that can give rise to the bulk tumor. Moreover, 
most tumors are heterogeneous and contain cells exhibiting different degrees of 
differentiation. This raises another question of how a differentiated cell is able to divide and 
generate cells of varying degrees of differentiation. To address these questions, an alternative 
hypothesis was introduced, which postulates that cancer is driven by a small population of 
cells known as cancer stem cells (CSCs). 
The cancer stem cell hypothesis proposes that a small population of cancer cells possesses 
stem cell properties of self-renewal and differentiation, and are the underlying drivers of 
tumor initiation. Together with their more differentiated progeny, CSCs build up and 
maintain the tumor mass. This cell population is currently defined by functional parameters 
based on experimental observations. Firstly, these cells must have the ability for long-term 
self-renewal. This allows the cells to have limitless regenerative potential to support the 
growth of the tumor. Secondly, the cells must possess the capacity to differentiate, giving rise 
to tumorigenesis and the heterogeneity that is seen in the tumor. Thirdly, these cells also have 
the ability to form tumors after xenotransplantation [3–5], and can be expanded in adherent 
culture whilst maintaining a very high percentage of CSC population [6].  
The study of CSCs is a very dynamic field, with constant changes and additions to our 
understanding as more research is done. The hypothesis that cancer could arise from the 
activation of dormant stem cells was first proposed by German pathologist Julius Cohnheim 
in 1875 [7]. This idea was strengthened with the first assay demonstrating the existence of 
this group of cells in vitro [8], and the observation that poorer patient prognosis was seen in 
germ cell tumors with the presence of undifferentiated cells in the residual tumor masses 
post-chemotherapy [9]. The first identification and characterization of cancer stem cells was 
in acute myeloid leukemia in 1997. By transplanting CD34+CD38- fractions from patients 
into mice, CSCs were able to recapitulate the same leukemic phenotypes seen in the patient 
[4]. Since then, more evidence of CSCs in different cancers has emerged, such as in multiple 
myeloma [10], breast cancer [3] and brain cancer [11,12].  
Despite the numerous studies, uncertainty still remains about the origins of CSCs and if this 
model is applicable to all cancer types. One study has shown that two populations of cells 
exist in squamous skin tumors, and evidence presented that the CSCs drove the development 
of the bulk tumor [13]. Lineage tracing has also shown that it is the CSC population that 
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contributes to the formation of the tumor [14]. With regards to the origin of CSCs, it was 
shown in some cancers that the CSC pool may have originated from normal tissue-resident 
stem cells that acquired oncogenic mutations that drove self-renewal [15,16]. This led to the 
formation of different subclones from the parental CSC, all of which continued to contribute 
to the growth of the bulk tumor [17,18] (Figure 1). Others have identified that CSCs arise 
from dedifferentiation of differentiated cancer cells due to the influence from the tumor 
microenvironment [19].  
Transplantation experiments in mice have yielded further evidence supporting the existence 
of CSCs. Transplantation of tumor cells that were pre-sorted to enrich for CSCs showed that 
they were up to 100-fold more efficient in tumor formation than unsorted bulk tumor cells 
[3,4,20]. However, the frequency of CSCs is highly variable depending on the type of cancer, 
and can range from below 1% as seen in acute myeloid leukemia [4], to 25% in melanoma 
[20]. CSCs are also relatively abundant in some cancers, such as acute lymphoblastic 
leukemia (ALL), where at least 50% are capable of forming tumor formation in wild type 
mice [21].  
The relative rarity of CSCs has led to the development of protocols for their isolation from 
solid tumors using various cell surface markers that were enriched in the cancer types. 
CD34+CD38- fractions determined the presence of CSCs in leukemia [4], while a 
CD44+CD24-/low profile was used to isolate CSCs from breast cancer [3]. CD133 (Prominin-
1) was used as a marker to isolate CSCs from glioblastoma multiforme, colorectal and 
pancreatic cancers. Despite multiple studies done to show the usefulness of using markers to 
isolate the CSCs, one has to pay attention to the use of these cell surface markers as a 
selection tool for CSCs as they may not be representative of the entire CSC pool. A good 
example of this was seen in leukemia where CD34+CD38- cells were thought to be the CSCs, 
only for it to be later shown that leukemia CSCs could also be seen in the CD34- and CD38+ 
populations [22–24]. Similarly, breast CSCs that were first identified by their CD44+CD24-
/low profile were later identified by different markers such as CD61 [25] and lin-CD29 
highCD24high [26]. It would appear that a combination of markers has to be employed while 
isolating these cells from bulk tumors and these markers have to be tested in a large number 
of patients. In the end, the most conclusive verification method is transplantation to check for 
tumorigenic property. 
Recent advances in genomics have generated large amounts of CSC sequencing data showing 
that CSCs carry a stem cell signature, which is often a prediction of poor prognosis and high 
propensity for relapse [27]. When comparing CSCs to stem cells, normal cells and 
differentiated cancer cells, it was found that CSCs often have a gene expression pattern that is 
most similar to that of the stem cells, which has been termed the “stem cell signature” 
[16,24]. This genomic data further demonstrates that CSCs have properties that resemble 
stem cells, which allow the cells to contribute to tumor initiation and growth, therefore giving 
CSCs their deadly reputation. 
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Figure 1. The evolution of cancer stem cells. Normal cellular hierarchy with stem cells that 
generate more restricted progenitor cells, which eventually give rise to the matured, 
differentiated cells. The cell of origin for a tumor could arise from an early progenitor cell, 
where the accumulation of mutations leads to the formation of a CSC. The CSC then 
continues to drive tumor growth by continuous self-renewal and the generation of 
differentiated cancer cells. Reprinted with permission from Nature Publishing Group: Nature, 
Visvader. (2011) [28] 
 
1.2 GLIOMA INITIATING CELLS 
Glioma is a common type of brain tumor and has been classified into four different grades 
based on morphological and histological features. The most malignant form is a grade IV 
glioma, also known as glioblastoma multiforme (GBM), which is associated with poor 
prognosis and has an average median survival of 15 months [29]. This high morbidity is in 
part due to the location of the cancer in the brain, which prevents adequate resection of the 
tumor. Despite the combination of surgery, chemotherapy and radiotherapy, more than 90% 
of the patients showed recurrence [30]. The recurrence is believed to be caused by the 
expansion of a distinct subpopulation of cells within the solid tumor that follows the CSC 
hypothesis. 
This subpopulation of immature cells in the highly lethal cancer, termed glioma initiating 
cells (GICs) [5,31–33], coexist with the differentiated cell populations in the bulk tumor. In 
2003, Singh et al described the presence of brain tumor stem cells (BTSCs) in human patient 
material, including the GICs. This group of cells was isolated based on enrichment for the 
neural stem cell surface marker CD133. In culture, the CD133+ cells isolated from the tumor 
were able to form neurosphere-like colonies and could be differentiated into tumor cells that 
resembled the original patient tumor [5] (Figure 2). The frequency of GICs in GBMs was 
estimated to range between 19-29%, and as few as 100 CD133+ cells were sufficient to 
produce tumors in mice, with xenografts exhibiting histopathological phenotypes matching 
the patient’s original tumor [11]. 
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Figure 2. Identification of GICs from solid tumors after dissociation. CD133 is used as a 
marker to identify the small population of cells within the tumor mass that can uniquely 
propagate the tumor. Reprinted with permission from Nature Publishing Group: Oncogene, 
Singh et al. (2004) [34] 
 
However, one must be aware of the heterogeneity that exists amongst patients. CD133 
received plenty of attention as the marker uniquely identifying GICs [5], and many studies 
were conducted without any further experimental validation. This was soon proven to be an 
erroneous generalization when various groups showed that CD133- cells were also capable of 
forming glioblastoma [35–38]. Moreover, CD133 alone or in combination with other 
markers, could be used to identify CSCs from other cancers such as prostate [39], lung [40] 
and liver [41]. Since then, differing opinions have surfaced on the utility of CD133 
expression as a good prognostic marker. Some studies have shown that high CD133 
expression in patient tumors often leads to poorer prognosis, and is correlated to shorter 
survival of the patients [42,43]. However, another study has shown that CD133 is actually 
correlated to longer survival after tumor recurrence [44]. This demonstrates that while CD133 
can be used as an indicator of the presence of GICs, it should not be taken to be the one 
marker for GICs. Further studies have to be done to find out the biological significance of 
CD133, as well as to assess its proper role in identifying GICs. 
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GICs can also be established as cell lines, both as spheres [5,31] and adherent cultures [6]. 
The adherent culture was shown to be a more efficient culture system where GICs could be 
propagated more stably than in sphere culture. This was attributed to the possibility of 
spontaneous differentiation and cell death in the sphere culture due to the non-uniform 
exposure to growth factors, oxygen and nutrients. The adherent culture condition on the other 
hand could fully suppress the differentiation of the GICs to oligodendrocytes and neurons, as 
shown by O4 and Tuj-1 stainings respectively. The adherent GICs showed high infiltration 
into the host brain when transplanted into mice. They also kept their tumorigenic properties 
and were able to generate tumors that exhibited pseudopalisading necrosis, nuclear 
polymorphism and microvascular proliferation, which are key histopathological features of 
human GBM tumors [45].  
The question of where do GICs arise from, and how similar they are to stem cells remains 
unanswered. GICs have been shown to share expression of stemness-associated genes with 
stem cell populations [27,46]. Functionally, it was demonstrated that GBMs contain 
tumorigenic neural stem-like cells that could be differentiated to GFAP-positive astrocyte-
like cells or Tuj1-positive neuron-like cells [33]. When compared to normal brain tissue, 
GICs exhibited enrichment in expression of genes normally associated with embryonic stem 
cells, which includes genes such as Oct4, Musashi and Sox2 [27]. GICs were also shown to 
have a gene expression profile that was more similar to that of fetal neural stem cells than of 
adult brain tissue [6], and it is proposed that this group of cells continuously resupply the bulk 
tumor cells through self-renewal and cell differentiation [6,7]. These observations indicate 
that GICs may originate from neural stem or progenitor cells, and they carry a stem cell 
signature that one might use as a predictive tool for prognosis. 
Gene expression profiling of gliomas as a predictive tool for survival gave us a more in depth 
look into the molecular classification of the cancer [47–49]. Gene expression studies showed 
that genetic signatures exist amongst the different grades of glioma, and gene expression-
based clustering of gliomas results in the emergence of groups with different survival and 
recurrence prognosis. Phillips et al first published a panel of molecular subclasses of the 
glioma samples, and showed that the different subclasses resembled different stages in 
neurogenesis. Neuronal differentiation markers such as OLIG2, MAP2, NeuN and DCX were 
expressed in the proneural subclass, while markers of NSCs such as VIM, NES and CD133 
were expressed in the mesenchymal and proliferative subclasses. Interestingly, the authors 
highlighted that it is the mesenchymal and proliferative subtypes that correlated to poorer 
prognosis. This indicated that signaling pathways involved in the maintenance of neurogenic 
potential play critical roles in tumor aggressiveness [49]. Verhaak et al extrapolated this study 
by utilizing genomic data from the Cancer Genome Atlas (TCGA) Research Network to 
identify two additional subtypes: classical and neural. This study yielded four subtypes of 
GBM that were determined by expression patterns, and this data was compiled and compared 
to gene expression from a collection of xenografts so as to determine the tumor subtype. The 
dataset was then compared to gene expression sets from neurons, oligodendrocytes, 
astrocytes and cultured astroglial cells, where each subtype was shown to be linked to a 
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possible cell of origin. This led to the current nomenclature for classification: proneural, 
neural, classical and mesenchymal. Whilst this data supported the finding of the proneural 
and mesenchymal subclasses as defined by Phillip et al, Verhaak et al also highlighted 
alterations in oligodendrocytic development gene PDGFRA as well as higher expression of 
SOX genes in the proneural signature. In the classical subtype, genes in the Notch and Sonic 
hedgehog pathway, as well as NES were highly expressed, and there were abnormalities in 
EGFR expression [50]. The authors also observed that the proneural signature predicted 
improved survival, which was supported in another independent study [51]. The evidence 
presented so far suggests that there might be stratification in the cell of origin of GICs, and 
patient prognosis is correlated with tumor classification into one of the characteristic groups 
with defining gene expression patterns. This suggests that tumor classification can also be 
used to help predict responses to therapy.  
GICs are highly resistant to chemo- and radiotherapy [52–54]. Radiation of human glioma 
xenografts, both in vitro and in vivo, led to the enrichment of the CD133+ population. This 
population of cells was able to initiate tumor growth upon transplantion into mice, therefore 
supporting the notion that it is the GICs that are crucial for recurrence [52]. GICs also 
exhibited resistance to temozolomide (TMZ), a chemotherapeutic agent commonly used for 
glioma treatment. It was also shown that TMZ affected NSC viability, but had minimal 
effects on GICs [54]. These properties of GICs prove to be a major challenge for therapies. 
Moreover, conventional therapies remove the bulk tumor and most of the differentiated 
glioma cells, whereas the relatively quiescent GICs are able to escape. These remaining GICs 
are suggested to then initiate the regrowth of the tumor [55], thus leading to relapse in 
patients. 
 
1.3 TREATMENTS TARGETING GICS 
Conventional cancer treatment involves the use of cytotoxic chemotherapeutic agents that 
target highly proliferative cancer cells. Most of these drugs have a cytostatic effect which 
block cells in various stages in the cell cycle.  Treatment for glioma patients is no exception, 
and for many years, a combination of surgery, radiotherapy and chemotherapy has been the 
gold standard of treatment for these patients. Despite such harsh strategies to combat the 
disease, prognosis remains poor and the median survival remains as low as 14-16 months 
[29]. 
Temozolomide (TMZ) is one of the common chemotherapeutic agents used as part of the 
current regiment to treat GBM patients. It is an alkylating agent that crosslinks DNA, 
therefore preventing cells from further division. TMZ was rapidly absorbed and showed 
relatively low toxicity to patients during preclinical studies, which has made TMZ the drug of 
choice for treatment [56,57]. Despite its effectiveness against differentiated glioma cells [58], 
GICs have exhibited resistance to TMZ due to their low proliferation rate and quiescent 
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nature. They are spared by TMZ treatment and can initiate the regrowth of the tumor 
[55,59,60], which leads to relapse in patients. 
Another cause for concern with TMZ treatment is its adverse effects on NSCs. While having 
no significant effect on GICs, it led to a reduction of NSC viability [54]. Since NSCs exists 
during childhood and persist during adulthood [61], TMZ treatment causes a chronic loss in 
neurogenic potential that could lead to detrimental side effects on learning and memory.  
Additionally, a recent paper has shown that differentiated glioma cells could go through a 
phenotypic shift to acquire a GIC-like status upon TMZ treatment [62]. This was 
characterized by reduced expression of the differentiation marker GFAP and an increase in 
stem cell markers CD133 and Sox2. This conversion rate was increased upon long term TMZ 
treatment, and could be yet another plausible explanation for the high rate of recurrence in 
glioma patients post treatment. 
With more studies that show the ineffectiveness of current chemotherapy treatments, there is 
an urgency to find more effective ways of treating glioma and specifically GICs. Various 
methods that have been proposed include inducing differentiation, targeting signaling 
pathways that are involved in GICs maintenance and function, or inhibiting their survival 
mechanisms. Bone morphogenetic proteins (BMPs) have been shown to induce 
differentiation in GICs, thereby inhibiting tumorigenicity in vivo [63]. The inhibition of 
Notch signaling was also shown to be effective in inducing differentiation of GICs [64] and 
reducing radioresistance [65]. Inhibition of STAT3 has been shown to disrupt GIC 
proliferation, as well as deplete stemness markers [66]. Micro-RNAs have also been 
suggested to be effective by affecting the apoptotic signaling pathways, which enhanced 
sensitivity towards chemotherapeutic agents [67].  
The discovery of GICs has altered our understanding of glioma tumor biology and has led 
researchers to reevaluate current therapies. Novel strategies targeting GICs are being 
developed, and more care is taken to understand the similarities and differences between 
GICs and NSCs so as to develop drugs that can specifically target the former cell type.  
 
1.4 CHEMICAL SCREENS – PARAMETERS USED 
High throughput chemical screening is a relatively fast and effective way to discover possible 
hit or lead compounds that shows efficacy against different diseases, including GBM and 
GICs. There are various parameters that one could consider when doing a screen. In the most 
ideal setup for drug screens, a uniform layer of cells are exposed to equivalent quantities of 
drugs in medium that does not hinder binding efficacy nor affect the rate of metabolism of the 
drug. Some clinically relevant parameters are then used as a readout to assess drug potency. 
Cancer cell survival is often used as a readout by measuring cell viability, which is the 
quantification of ATP amounts in a cell. It has proven to be fast and accurate in deriving dose 
responses.  
 8 
The above requirements make neurosphere GIC cultures poorly amenable to chemical 
screening. The 3D growth results in uneven drug exposure, and spontaneous differentiation 
and cell death in each sphere adds noise and may result in false-positive data. However, 
Pollard et al made drug screening for phenotypes in GICs tractable with their adherent culture 
protocols in 2009 [6]. They managed to maintain a relatively pure and stable culture that 
exhibited no major changes from the parental population in early passages, and have 
suggested that each GIC line be expanded for no more than 20 passages.  
Following identification of a potential hit compound, the mechanism of cell death is often 
looked. This gives us an understanding of the signaling pathways that could be involved, as 
well as determine if the drug might be useful in clinical trials. Listed below are brief 
overviews of the different types of cell death classified into two groups based on today’s 
nomenclature: conventional (programmed) and non-conventional. 
1.4.1 Conventional (programmed) cell death 
Apoptosis is a type of programmed cell death that leads to characteristic morphological 
changes such as cell rounding and shrinkage, nuclear fragmentation, chromatin condensation 
and membrane blebbing [68].  Different signaling cascades are implicated: for example the 
involvement of death receptors such as FAS, the involvement of BCL-2 family members in 
mitochondrial outer membrane permeabilization or the involvement of cytochrome c due to 
sustained elevated levels of calcium (Ca2+), all of these finally lead to the activation of 
downstream caspase cascade that is then the effector of apoptosis [69]. Caspase-independent 
apoptosis has also been shown to occur by inhibiting ATP synthesis or the respiratory chain, 
or by increasing ROS production [70]. Apoptosis markers such as cleaved caspase-3 and 
annexin-V are commonly used in screens. 
Outside of the mitochondria, which are widely known to be key in apoptosis induction, the 
endoplasmic reticulum (ER) has also been established to partake in apoptosis. It is widely 
known to be an internal Ca2+ store, and it was shown that BCL-2 is able to regulate Ca2+ 
efflux from the ER, thereby controlling the onset of apoptosis [71]. Moreover, the ER plays 
an important role in Ca2+ homeostasis by taking up excess intracellular Ca2+. Any aberration 
of this process will lead to a deregulation of Ca2+ homeostasis and drive the cells to apoptosis 
[72] (Figure 3). 
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Figure 3. Involvement of ER in apoptosis. Reprinted with permission from Elsevier: Cell 
Calcium, Berridge (2002) [73] 
 
Autophagy was initially thought to have a pro-survival role in cell homeostasis that sets in 
during periods of starvation and stress. It is a catabolic process that allows the cell to “ingest” 
its own organelles via digestion within double membrane-bound structures known as 
autophagosomes [74]. However, accumulating evidence shows that if cells are unable to cope 
with the stress, autophagic cell death can also occur [75,76]. It is often accompanied by the 
presence of modulators such as members of the ATG family [77]. ATG8, or the mammalian 
homolog LC3, is commonly used as a readout for autophagic activity in most assays, 
including high-throughput screens [78,79].  
Necrosis has long been thought to be an accidental type of cell death that is not controlled by 
any molecular mechanisms. It is morphologically characterized by cell swelling, organelle 
dysfunction and cell lysis [80]. However, recent evidence has shown that necrosis is 
intricately regulated by various signaling pathways, including the activation of 
serine/threonine kinases [81].  
From a therapeutic perspective, necrosis is not a preferred choice of cell death as the release 
of the cell contents will cause immune cells to release pro-inflammatory cytokines [82], 
which triggers inflammation and may further exacerbate the condition. In contrast, cell 
membrane integrity is maintained during apoptosis, and apoptotic cells are cleared by 
phagocytes [83], therefore immunogenic response will not being elicited [84]. Similarly, 
autophagic cell death has been shown to reduce inflammatory reactions [85] and inhibit pro-
inflammatory signaling [86].  
1.4.2 Non-conventional cell death 
Paper I in this thesis revealed an example of non-conventional cell death by 
macropinocytosis. Macropinocytosis is the process of absorbing extracellular fluids, solutes 
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and small particles on the plasma membrane via the formation of large uncoated vacuoles 
[87]. It is a transiently triggered process and operates for a limited period of time [88]. 
Macropinocytosis has been observed since the 1970s in human glial cells upon the addition of 
growth factors [89]. It was only in 2008 that a comprehensive study showed 
macropinocytosis as a form of cell death due to the activation of Ras in glioblastoma cells 
[90]. In this study, electron-lucent vacuoles were observed upon active Ras expression with 
the use of electron microscopy. These vacuoles were further distinguished from 
autophagosomes by the lack of expression of the autophagy marker LC3. There was also no 
activation of apoptotic markers, yet this process led to eventual cell death by a massive 
increase in fluid uptake, resulting in cell swelling and membrane rupture. This novel non-
apoptotic type of cell death was coined as methuosis.  
A follow-up study showed that methuosis could be induced by small molecules. The group 
did a screen based on compounds that induced cell vacuolization, and the hit compounds 
exhibited the phenotypic characteristics of methuosis. It was also revealed that Rab5 and 
Rab7, genes that are involved in the endosomal trafficking pathway, were implicated in the 
process. A significant decrease of Rab5 was observed, followed by an increase in Rab7 
activity upon treatment, suggesting that the compound might be targeting proteins in the 
endosomal complex, thereby allowing the vesicles formed to bypass the normal endosomal 
trafficking pathway. The vesicles accumulate and undergo fusion, eventually filling up the 
cell, impairing metabolic functions and causing cell death [91] (Figure 4). 
 
Figure 4. Schematic of the induction of methuosis. This abnormal form of macropinocytosis 
lacks the components for normal fusion with lysosomes, therefore leading to the 
accumulation of vacuoles which fill the cell and disrupts membrane integrity. Reprinted with 
permission from BioMed Central Ltd.: Molecular Cancer, Overmeyer et al. (2011) [91] 
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In Paper I, we have shown that mitogen-activated protein kinase kinase 4 (MKK4) activation 
was implicated in the formation of macropinocytosis. MKK4 is a member of the MAP kinase 
kinase family, and directly phosphorylates c-Jun N-terminal kinases (JNK) to elicit various 
types of cellular responses such as inflammation, apoptosis, growth and differentiation [92]. 
MKK4 is also involved in the p38 cell stress pathway, resulting in the activation of 
transcription factors that control functions such as cytokine production and apoptosis [93].  
Methuosis is a novel concept of cell death, and the underlying molecular signaling and 
mechanisms are still not fully understood. It is still left to be identified if methuosis is 
induced in a controlled manner via specific targets, and if so, what the identities of these 
targets might be.  
 
1.5 ION HOMEOSTASIS 
Ion homeostasis is the process of maintaining the concentrations of cations and anions at a 
steady-state level in a cell, and this is governed by the actions of ion channels, pumps and 
transporters. Ion channels are one of the fundamental groups of proteins that are found on 
every cell. They have long been assigned the role of governing basic cellular processes such 
as establishing a resting membrane potential, maintaining intracellular osmolarity, regulating 
cell volume and shaping action potentials in excitable cells. Recently, they have also been 
shown to control cell cycle in embryonic stem (ES) cells and neural stem cells (NSCs) [94]. 
For example, ion flux through potassium and calcium (Ca2+) channels has been shown to 
control diverse functions as proliferation and migration in stem cells and cancer cell lines, 
including glioma [95,96]. 
1.5.1 Calcium 
Ca2+ is known to be a very versatile intracellular signal molecule that can effect and regulate 
many different cellular processes. Even in non-excitable cells, a 20,000 fold gradient exists 
between the intracellular and extracellular concentrations of Ca2+, where upon stimulation, 
the levels of intracellular Ca2+ can increase from approximately 100 nM to > 1 µM [97]. 
Moreover, the life and death choices of the cell hang on a very delicate balance in the levels 
of intracellular Ca2+. With such complexity and variety in signaling and functions, it is 
necessary for the cell to exert tight control over Ca2+ levels. 
One way of achieving Ca2+ homeostasis is via the compartmentalization and storage of Ca2+ 
into intracellular organelles, such as the endoplasmic reticulum (ER) and mitochondria. Such 
methods of storing Ca2+ allows for rapid and immediate release of Ca2+ when necessary, as 
well as allowing rapid uptake of Ca2+ when the cell is met with a sudden rise in Ca2+ levels, 
therefore preventing any irreversible damage to cellular function. Ca2+ stores also have very 
different functions. Mitochondrial Ca2+ has been shown to be a key regulator of both 
metabolism [98,99] and apoptosis [100], whereas Ca2+ from the ER is mainly involved in 
regulation of apoptosis [72].  
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Ca2+ homeostasis is a highly coordinated process that involves a large number of signaling 
components. It can be summarized into four different units (Figure 5):  
1. Signaling – The conversion of stimuli to Ca2+ signals. 
2. ON mechanism – Ca2+ influx. 
3. Decoding – Ca2+-sensitive processes triggered to elicit physiological responses. 
4. OFF mechanism – Removal of Ca2+ and restoration of basal intracellular Ca2+ 
levels. 
 
 
Figure 5. The four units of Ca2+ homeostasis. Reprinted with permission from Nature 
Publishing Group: Nature Reviews Molecular Cell Biology, Berridge et al. (2000) [101] 
 
1.5.1.1 Signaling 
A diverse range of stimuli binds to various cell surface receptors and trigger the start of Ca2+ 
signaling by different second messengers. One example is the activation of inositol-1,4,5-
triphosphate (Ins(1,4,5)P3), which in turn binds to inositol-1,4,5-triphosphate receptor 
(InsP3R) to induce the release of Ca2+ from the ER [102]. This will initiate the ON 
mechanism. 
1.5.1.2 ON mechanism 
The ON mechanism is induced by an elevation of intracellular Ca2+ levels, which is supported 
from two different groups of sources. Firstly, external sources of Ca2+ can be introduced into 
the cell via different classes of Ca2+ channels, such as the voltage-gated Ca2+ channels 
(VGCCs) or receptor-operated channels. For example, ionotropic glutamate receptors are able 
to induce Ca2+ influx in the presence of glutamate [103]. Secondly, internal sources of Ca2+ 
come from the organelle stores such as the ER and mitochondria. Ca2+ release from the ER is 
mainly facilitated by the InsP3R and ryanodine receptor (RYR) families [104].  
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1.5.1.3 Decoding 
Various Ca2+ binding proteins are required to “translate” the Ca2+ signals to physiological 
responses. Two groups of Ca2+ binding proteins exist: effectors and buffers. They have 
opposing effects, and it is the balance between the groups that controls the various cellular 
processes [105].  
The Ca2+ binding then evokes gene transcription via Ca2+-dependent transcription factors that 
are activated by different mechanisms. One example is the activation of nuclear factor of 
activated T cell (NFAT) by repetitive Ca2+ spikings [106], which is known to effect a variety 
of downstream processes, such as immune response and the development of skeletal muscles 
[107]. The Ca2+ dependent transcriptional changes are also implicated in differentiation in 
various cell types, including neural cells [108,109].  
1.5.1.4 OFF mechanism 
Once the desired signal is achieved, basal Ca2+ levels are restored by removing Ca2+ through 
different exchangers and pumps. This includes the Na+/Ca2+ exchanger (NCX), plasma 
membrane Ca2+-ATPase (PMCA) and sarco/endoplasmic reticulum Ca2+-ATPase (SERCA). 
Both NCX and PMCA extrude Ca2+ out of the cell, while SERCA pumps Ca2+ back into the 
ER [97]. 
One way of studying the effects of Ca2+ homeostasis is to employ compounds that target the 
different Ca2+ ion channels and pumps. Below is a general overview of the three different 
types of compounds that we have used in Papers II and III, and their different modes of 
action. 
1.5.2 A23187 
A23187 is a well-known carboxylic acid antibiotic that plays the role of a Ca2+ ionophore 
[110]. The compound forms a dimer that complexes with Ca2+ and transports the ion through 
the plasma membrane [111], resulting in a rapid increase in intracellular levels of Ca2+ [112]. 
This leads to the depletion of Ca2+ from the intracellular stores [113], which activates plasma 
membrane Ca2+ channels to allow an influx of Ca2+ into the cell [114]. The sustained high 
levels of Ca2+ in the cells were thus maintained for periods of time, resulting in apoptosis. 
1.5.3 Thapsigargin 
Thapsigargin is another well-established compound that affects Ca2+ homeostasis, in this case 
by irreversibly inhibiting the SERCA pumps [115]. This raises the levels of intracellular Ca2+ 
by blocking the cell’s ability to pump Ca2+ back into the ER, and more importantly, causes 
the depletion of Ca2+ stores, which similarly to A23187, activates plasma membrane Ca2+ 
channels to allow influx of Ca2+ into the cell [114]. This disruption to Ca2+ homeostasis 
drives the cell into apoptosis.   
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1.5.4 Niguldipine 
Niguldipine is classified under the group dihydropyridines, and was discovered to be an 
antihypertensive agent due to its vasodilator activity [116,117]. This activity was due to its 
binding to the T- and L-type VGCCs [118] and alpha 1-adrenoceptors [119]. More recently, 
Niguldipine has been shown to induce autophagy in glioma cells [79], and can cause a 
reduction of cell viability to GICs in our study, as shown in Paper III. This shows that there is 
much potential in old pharmaceutical compounds, which is reflected in the current trend to 
reposition these compounds in cancer therapy. 
1.5.5 Involvement in cancer 
In cancer research, Ca2+ has been implicated in a variety of processes, including cancer cell 
survival [120]. Due to the intricate nature of the balance of intracellular Ca2+, researchers 
have been exploring with the idea of driving cancer cells to choose the death pathway by 
influencing intracellular Ca2+ levels. It was recently shown that interference with a Ca2+ 
channel subunit was able to drive liver tumor-initiating cells into apoptosis [121]. 
Due to the wide spectrum of signaling pathways Ca2+ is involved in, the deregulation of Ca2+ 
homeostasis can also cause tumor progression. Cancers have been shown to carry altered 
expression of Ca2+ related genes, with some of the alterations being correlated with 
prognosis. Many types of Ca2+ channels have aberrant expression in cancer cells. One 
example is the transient receptor potential (TRP) channels, a superfamily of Ca2+ channels. 
Inhibition of TRP channel activity suppressed glioma growth [122], and increased expression 
has been observed in prostate [123], colon [124] and bladder cancer [125]. Another example 
is seen in the overexpression of T-type VGCC that resulted in increased cell proliferation in 
glioma [126] and esophageal carcinomas [127]. Aside from Ca2+ channels, overexpression 
and aberrant activation of the Ca2+ dependent transcription factor NFAT have also been 
observed to play a role in tumor progression in various types of cancer, including pancreatic 
[128], breast [129] and melanoma [130]. NFAT has also been implicated in promoting 
angiogenesis [131].  
With a plethora of effects, targeting Ca2+ related genes and proteins in cancer therapy have 
garnered plenty of interest as more evidence established the importance of Ca2+ homeostasis. 
Strategies involve driving cancer cells towards differentiation, inhibiting cell proliferation 
and increasing sensitivity to apoptosis by controlling and affecting the Ca2+ pathways. 
However, due to the ubiquitous behavior of Ca2+ signaling, selective targeting of components 
in cancer cell and CSCs remain to be a major challenge. 
Proliferation of glioma cells has been shown to be inhibited by the L- and T-type channel 
blocker mibefradil, and the cells are driven to apoptosis [132,133]. Mibefradil also increased 
survival when used together with conventional treatments such as radiosurgery in vivo [134], 
as well as sensitized TMZ resistant glioma cells, enhancing the efficacy of TMZ [135]. It 
remains to be seen if this combination of treatments is able to overcome the resistance seen in 
GICs to TMZ treatment [53].  
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The idea of using ion channel modulation as a form of therapy for targeting GICs has only 
recently emerged. The relationship between ion channels and GICs remains obscure, however 
present studies imply that the expression of ion channels and Ca2+ related genes are abnormal 
in GICs. This idea was corroborated by our findings in Paper II and III. 
 
 
 

  17 
2 AIMS 
The overall aim of this thesis was to find small molecules that can be used as potential 
treatments against GICs, and to try to understand how these agents work in GICs.  
The specific aims were:  
• To find compounds that target GICs via a small-to-medium drug screen.  
• To investigate how ion channel antagonists and inhibitors affect GIC viability as compared 
to their differentiated counterparts and normal cells.  
• To investigate how ion fluxes, specifically those essential to Ca2+ homeostasis, could effect 
GIC viability. 
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3 RESULTS AND DISCUSSION 
3.1 PAPER I 
3.1.1 Small molecule screening revealed rapid and specific GIC death 
induced by Vacquinol-1 
Small molecule screens have often been used to find potential hit compounds targeting cancer 
cells, however the screens are usually more simple, looking at only one or a couple of 
aspects, such as: 1) cell death monitored with the use of caspase 3 or Annexin V; 2) 
autophagy using LC3; or 3) cell viability using an ATP or MTT based assay. In this paper, 
we have conducted a screen covering all the above mentioned parameters, and sieved out the 
hit compounds that were seen to affect the GICs only, yet spare all normal cells such as 
mouse ES cells (mESC) and human fibroblasts. 
We started with a library of 1364 compounds and conducted a phenotypic screen on the 
GICs, which rendered 234 compounds. Further counter screens using mECSs and human 
fibroblasts were done to identify 63 compounds that had an effect on GICs only. We then 
used a recovery assay to filter out compounds that caused an irreversible effect on the GICs, 
combined with in silico absorption, distribution, metabolism and excretion (ADME) 
prediction, we were left with 17 potential compounds, which were then thoroughly examined 
using the following assays: 1) Selectivity was tested by setting up a hanging drop-based 
mixed culture using GICs and fibroblasts; 2) Toxicity was tested by administering the drugs 
to zebrafish embryos; 3) Cardiovascular toxicity was checked using ex vivo zebrafish hearts 
and 4) in vivo efficacy was monitored by xenotransplanting labeled GICs into zebrafish. This 
battery of thorough testing revealed Vacquinol-1, which was a potent drug that passed all 
criteria necessary if one would like to push this compound into clinical trials. In summary, 
Vacquinol-1 displayed high cytotoxicity, significantly reduced GIC viability and was able to 
selectively target GICs. 
3.1.2 Vacquinol-1 induced cell death via an unconventional pathway 
We proceeded to check for the mechanism of cell death, and discovered that Vacquinol-1 did 
not act via the apoptotic pathway. Apoptosis inhibitor Q-VAD only modestly rescued cell 
death in Vacquinol-1 treated cells, and Vacquinol-1 did not elevate levels of cleaved caspase 
3, nor caspase 3 and caspase 7 enzymatic activity. We also checked if GIC death was caused 
by mitochondrial death pathway. Tetramethylrhodamine ethyl ester (TMRE) incorporation 
was not increased, indicating that there was no disruption in the mitochondria. Autophagy-
associated cell death was also ruled out as there was no increase in LC3-II in GICs upon 
treatment. 
Vacquinol-1 treatment led to an increase in vacuole formation, whereby vacuole numbers 
increased in a dose-dependent manner. The vacuoles were a result of macropinocytosis, as 
shown by increased uptake of the tracer lucifer yellow. This uptake was significantly reduced 
when the cells were co-treated with drugs such as Bafilomycin A1, Dynasore and 
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Cytochalasin D, which have been shown to perturb macropinocytosis activity. Further 
transmission electron microscopy analysis confirmed massive vacuolization in cells, as well 
as swollen ER and mitochondria and distorted nuclear membrane structures. The vacuoles 
formed by Vacquinol-1 treatment were also shown to recruit the late endosomal and 
lysosomal marker, lysosomal-associated membrane protein (LAMP1). These provided 
evidence that Vacquinol-1 induced massive macropinocytosis, leading to catastrophic 
vacuolization and a necrotic-like cell death. 
We used a shRNA screen to identify the pathways involved in vacuolization, and found that 
MKK4 had a critical role to play in the process. Vacquinol-1 treatment led to a rapid 
activation of MKK4, and knocking down the gene (MAP2K4) in GICs led to a huge 
reduction in uptake of lucifer yellow upon Vacquinol-1 treatment. Although the involvement 
of MKK4 activation in macropinocytosis is not fully understood, one can speculate of its 
involvement downstream of Ras-activated Rac1, which is induced during periods of cellular 
stress. These are pathways that have been implicated in apoptosis [136] and autophagy [137], 
and due to the complexity and cross-talk between the different pathways [138], it could be 
speculated that the response machineries of methuosis share common signaling pathways 
with the more well established death pathways. 
 
3.1.3 Vacquinol-1 led to the attenuation of tumor growth in vivo and 
prolonged survival 
Zebrafish xenograft glioblastoma model showed that the GICs could rapidly expand to form a 
tumor mass that started to infiltrate into the brain, which was stopped with Vacquinol-1 
treatment. In the mouse xenograft glioblastoma model, similarly, all the mice presented large 
and highly vascularized tumors that infiltrated into the brain, with the presence of massive 
areas of necrosis in 7 weeks. Vacquinol-1 was administered intracranially only 6 weeks after 
engraftment, and despite the advanced stage of GBM, the whole brain showed improved 
morphology with a smaller area of necrosis. There was increased LAMP1 staining in the 
tumor cells of Vacquinol-1 treated mice, showing that a similar initiation of macropinocytosis 
and the activation of methuosis occured in vivo. The effective dose of Vacquinol-1 also had 
no effect on the host brain, showing that the drug has the capacity to attenuate tumor growth 
in vivo. 
We then explored the bioavailability of Vacquinol-1 in vivo via oral, intravenous and 
intraperitoneal administration, and showed that Vacquinol-1 showed good penetrance into the 
brain, had maximal plasma exposure and was highly stable in vivo with very low systemic 
plasma clearance. This suggested that Vacquinol-1 could be administered orally, and we 
showed that the oral route of administration did not diminish the therapeutic effects of 
Vacquinol-1. Even when treated orally, the mice showed normal brain morphology, had a 
normalized brain weight and vastly improved survival, where only two out of the eight 
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Vacquinol-1 treated mice died during the 80 days of experiment. This is a vast improvement 
as compared to vehicle-treated mice, where median survival was only 31.5 days.  
The screen has led to the identification of a small molecule that can selectively target GICs by 
initiating non-apoptosis related cell death. This novel way of cell death by the induction of 
macropinocytosis, otherwise known as methuosis, did not lead to any adverse side effects in 
the mice during treatment. This could be another preferred method of inducing cell death in 
cancer treatments. With all the evidence presented, Vacquinol-1 shows high potential for 
clinical trials.  
 
3.2 PAPER II 
3.2.1 Differential expression of Ca2+ homeostatic genes identified in GICs 
With the ease and availability of RNA sequencing, global gene expression, or transcriptome 
studies, have been incorporated into glioma research. It is known that GBM is a 
heterogeneous disease, where each patient’s tumor and condition is different. To be able to 
classify GBM into different subtypes, different research groups have embarked on the study 
of gene expression [6,49,50,139]. The cells that were used by Pollard et al have also been 
investigated using microarray. However, microarray data displays high background and is not 
deep enough to uncover different isoforms and genes, thereby resulting in a loss of vital 
information. 
From our RNA sequencing data, we have uncovered a plethora of genes that were not picked 
up by the microarray done by Pollard et al. These genes are mainly involved in Ca2+ ion 
binding and channel activity. As mentioned by Berridge et al. [140], Ca2+ homeostasis is 
maintained by two groups of proteins – effectors and buffers. Our data revealed that GICs 
could be split into two groups – NSC-proximal GICs and NSC-distal GICs. The NSC-
proximal GICs had a higher expression of the effectors, whereas the NSC-distal GICs had a 
higher expression of Ca2+ buffers, which we have also corroborated by western blot analysis 
of the Ca2+ effector GRIA1 and the Ca2+ buffer S100A6. 
3.2.2 GIC sensitivity to Ca2+ modulators followed transcriptome rank order 
relative to NSCs 
To confirm the gene expression analysis, we tested two Ca2+ modulators on different GIC cell 
lines. Both the antibiotic A23187 and the SERCA pump inhibitor Thapsigargin treatments 
revealed a sensitivity rank order that was based on the GIC cell line’s proximity to NSC in 
gene expression, where the NSC-distal GIC lines were less sensitive to the Ca2+ perturbations 
caused by the drugs. 
We selected A23187 it should not be affected by gene expression, since it is an ionophore 
which can physically manipulate the cell membrane to allow entry of Ca2+ ions.  
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We further investigated if this trend would extend to the more differentiated end of the 
spectrum by using serum-differentiated GICs. Upon treating the differentiated GICs with 
A23187, we discovered that the effects on cell viability were not as severe as compared to 
their undifferentiated counterparts, which further corroborated our earlier finding.  
3.2.3 GIC sensitivity rank order to Ca2+ modulators correlated to NES, BLBP 
and GRIA1 expressions 
Correlation analysis of NSC marker gene expression and sensitivity to Thapsigargin 
treatment was performed in nine additional GIC lines, revealing that both NES and BLBP 
were linked to the elevated sensitivity to Ca2+ seen in GICs. The analysis also corroborated 
our earlier finding that GRIA1 is also correlated to GIC sensitivity to Ca2+.  
Further correlation analysis of genome wide mRNA levels and sensitivity to Thapsigargin of 
the nine GIC lines led to the identification of a further 785 correlated genes. Gene ontology 
analysis identified the commonality between these to be their involvement in Ca2+-mediated 
signaling.  
In order to improve our stringency levels, we set a higher threshold on the Thapsigargin 
sensitivity in the correlation analysis and had 385 genes in this data set. To further stratify the 
genes that are related to stemness, more stringent filters were applied by first comparing this 
data set to genes that were upregulated in the NSC-proximal GIC line, followed by another 
filtering process by comparing the genes to genes that were downregulated after 
differentiation. Nine genes were identified in this process, where three genes, including 
GRIA1, were linked to Ca2+ homeostasis.  
3.2.4 Drug reactome analysis identified Ca2+-induced gene expression 
We then decided to identify the underlying differences that resulted in differential 
intracellular Ca2+ responses to perturbations in the GICs. We selected the NSC-proximal GIC 
line, GliNS1 and the most NSC-distal GIC line, G166NS, and treated them with A23187 for 
7 hours. The time was sufficient to elicit the first few waves of transcriptional events [141]. 
We plotted the genes with altered expression after drug exposure against the mean expression 
value before drug exposure to identify robustly altered genes with potential biological 
significance. A very similar set of genes was altered in both cell lines, including Ca2+–binding 
genes such as HSPA5 and HSP90B1, and Ca2+–related ER stress response genes such as 
HERPUD1 and CALR. The Ca2+–activated transcription factor NFATC2 was also clearly 
induced in both lines. However, GliNS1 clearly induced a more significant transcriptome fold 
change than G166NS, suggesting that there is a more potent onset of Ca2+ signaling in the 
NSC-proximal GIC line. 
Interestingly, a set of anti-apoptotic genes was upregulated in G166NS. This suggests that, in 
addition to the lower sensitivity to Ca2+ perturbations, the NSC-distal GIC line could be better 
equipped to cope with external stress factors and is therefore less sensitive to the drugs used, 
including the apoptosis inducer Thapsigargin.  
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Moreover, since Ca2+ has been implicated in differentiation and in the state of stemness of 
stem cells, one could speculate that different levels of Ca2+ homeostasis reflect a stemness 
hierarchy based on the correlation of Ca2+ sensitivity to Nestin.  
 
3.3 PAPER III 
3.3.1 Chemical library screen revealed GIC sensitivity towards Ca2+ 
modulators 
We performed a chemical library screen using 72 ion channel modulators testing their effects 
on GIC viability. We obtained 11 hit compounds, where 10 of them were Ca2+ channel 
modulators. This further strengthened our finding in Paper II, where GICs were also shown to 
be sensitive to Ca2+ perturbations. 
3.3.2 Niguldipine is selective for undifferentiated GICs 
Niguldipine was among the ten Ca2+ channel modulating compounds. It was observed to have 
a less severe effect on differentiated GICs, normal NSCs and human fibroblasts as compared 
to undifferentiated GICs.  
There also seems to be a small therapeutic window where Niguldipine has a less toxic effect 
on NSCs as compared to the GICs. This would be an important factor for drug therapy 
against GBM, especially in children. Current treatment stratergies of pediatric brain tumors 
often impede the normal neural development of children, as the drugs used in chemotherapy 
ends up affecting normal cells, including NSCs. This implies that Niguldipine is a potential 
lead drug that could be further exploited to create a new analog. 
3.3.3 Effects of Niguldipine is not via α-adrenergic receptor signaling 
Dihydropyridines like Niguldipine are notorious to have polypharmalogical profiles. It has 
long been established that Niguldipine is a α-adrenergic receptor blocker, hence we decided 
to investigate if the effects on cell viability could be due to the α-adrenergic receptor 
signaling pathway. We treated the GICs with a panel of known adrenergic receptor 
antagonists that included the selective α1-adrenergic receptor antagonists, Prazosin 
hydrochloride and Terazosin hydrochloride. All the drugs except Prazosin hydrochloride had 
no effect on GIC viability, strongly suggesting that the effects elicited by Niguldipine were 
not via α-adrenergic receptor signaling.  
Interestingly, seven of the hit compounds were known to affect VGCCs, including 
Niguldipine. This strongly suggests that the VGCCs might have a role to play in affecting 
GIC viability. Since there is widespread expression of the CACNA1 family genes in GICs, it 
is difficult to pinpoint the specific VGCC that plays a central role in controlling GIC survival. 
We propose that it could be a concerted effect from multiple VGCCs, combined with the fact 
that, as we showed in Paper II, GICs are more sensitive to Ca2+ perturbations. This 
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combination leads to an imbalance in Ca2+ homeostasis, the inability of GICs to cope with 
stress, and eventual cell death. 
One possible mechanism of cell death is via nutrient starvation that is caused by the 
deregulation of ion dependent transport due to imbalance in ion fluxes initiated by disturbed 
Ca2+ homeostasis. We have shown that uptake of glutamate, which can be transported into the 
cell by the sodium dependent excitatory amino-acid transporter (EAATs), was affected upon 
treatment with some of our hit compounds, including Niguldipine. It has been shown that 
EAATs can be affected by the NCX [142], which in this case is affected by the Ca2+ fluxes.  
3.3.4 Niguldipine reduced tumor cell numbers and improved survival rates 
while having no adverse effect on cardiac rhythmicity 
Following the footsteps of Paper I, we proceeded to test if Niguldipine has an effect on 
cardiac rhythmicity by using a zebrafish ex vivo cardiac assay. We ruled out any side effects 
on the heart with Niguldipine as it did not affect the heart rhythm. The zebrafish xenograft 
glioblastoma model showed that Niguldipine could stop the formation of tumor mass of the 
GICs.  
In the murine xenograft model, Niguldipine treatment resulted in a significant improvement 
in median survival of the drug treated group as compared to the vehicle treated group. The 
evidence that we have gathered suggests that Niguldipine, which is well known as an anti-
hypertension drug, has the potential to be repositioned as a compound that targets GICs.  
The sensitivity to Ca2+ perturbations in GICs that we have seen in Paper II and III suggest 
that the difference in expression of Ca2+ related genes in malignant and normal cells have a 
significant contribution to the survival of GICs. Since Ca2+ is intricately linked to cell cycle, 
proliferation and death, and has been shown to oscillate during cell cycle in ES cells [143], it 
would be no surprise that GICs would have a Ca2+ homeostatic profile that is more similar to 
that of stem cells than differentiated cells.  
 
  
  25 
4 CONCLUSIONS AND FUTURE PERSPECTIVES 
From the work presented in this thesis, we can conclude that: 
1. Drug repositioning – known small molecules may have an potential as therapy against 
GICs.  
2. Vacquinol-1, A23187, Thapsigargin and Niguldipine are compounds that have the 
ability to kill GICs. 
3. Vacquinol-1 treatment caused the onset of methuosis, a novel kind of non-apoptotic 
cell death. 
4. A stemness associated Ca2+ sensitivity exists in GICs, and can be used to target this 
group of cells by perturbing cytosolic Ca2+ levels via channel blockers and inhibitors. 
With the identification of GICs, there is now a scramble to search for small molecules that 
can target this group of cells in hope of improving therapy for GBM patients and reducing the 
recurrence and mortality rate. We have identified a few compounds that exhibit selectivity 
towards GICs, with three of them being tied to Ca2+ homeostasis. Further work will be 
needed to determine if more ion channel modulators have the potential to be used for GBM 
treatment, as well as to explore the mechanisms involved. It will be interesting to determine if 
the level of stemness is directly coupled to Ca2+ sensitivity. Validation in vivo is also 
necessary for the three compounds before one is able to assess their potential for clinical 
trials. In summary, the search for a viable therapy against GBM and GICs, whether together 
with the conventional methods or as an adjuvant therapy, is still ongoing.  
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